AVRO News and Press, AVROBIO Inc. From 03/17/22

Provided interim data at WORLDSymposium™ 2022 that showed sustained engraftment across first three patients 1 + year post-gene therapy in Phase 1/2 clinical trial i for cystinosis; all remain off oral cysteamine to date Interim clinical data update of AVR-RD...

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences: C...

The following slide deck was published by AVROBIO, Inc. in conjunction with this event. For further details see: AVROBIO (AVRO) Presents At AVROBIO WORLD Symposium 2022 Cystinosis

Buying Penny Stocks Today? Here’s What You Need to Know After a very volatile few weeks of trading for penny stocks and blue chips, investors are cautiously optimistic about the future. While interest rates and geopolitical tensions have been driving market upsets recently, we&#x...

US Ecology ECOL +23% Republic Services is said in talks to purchase US Ecology. Enphase Energy ENPH +22% on Q4 results. ERYTECH Pharma (NASDAQ:ERYP) +13% expands patent portfolio for the treatment of rare metabolic diseases. Biofrontera (NASDAQ:BFRA) +12%. AVROBIO (NASDAQ:...

AVROBIO (NASDAQ:AVRO) is trading ~11% higher in the pre-market on Wednesday after the company reported data from an ongoing Phase 1/2 clinical trial for AVR-RD-04 in adults with Cystinosis. Cystinosis is a condition characterized by the accumulation of cystine in the cellular compon...

Sustained engraftment observed across first three patients 1+ year post-gene therapy; all remain off oral cysteamine to date Reduction in number of cystine crystals as measured in skin and intestinal mucosa biopsies observed across first three patients Continued favora...

The following slide deck was published by AVROBIO, Inc. in conjunction with this event. For further details see: AVROBIO Inc. (AVRO) Reprioritizes Pipeline Programs, Presentation - Slideshow

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Avrobio (NASDAQ:AVRO) granted non-statutory stock options for the purchase of up to 167K shares to three new employees; it granted 2,667 restricted stock units to one new employee. The stock options and RSUs were granted with an exercise price of $1.95/share for each stock option. The stock o...